Hims & Hers Health, Inc. (HIMS) is facing a securities fraud class action lawsuit from the FTC and state plaintiffs, alleging misconduct including deceptive health data sharing and violation of the ROSCA.
Why it matters. Investors in Hims & Hers Health may face significant financial losses, and the company's reputation and operations could be severely impacted.
whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
erasing over $970 million from the company's market capitalization in a single day.
The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%)
whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA)
Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including **Meta Platforms (Facebook)** and **Snap**, via embedded tracking pixels and customer list matching.
Hagens Berman's team has secured more than $2.9 billion in this area of law.
as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.
SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious busi…
The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).
